From October 15th to 17th 2023, the United European Gastroenterology Week (UEGW) took place in Copenhagen. The BÜHLMANN team presented two posters focusing on standardization of calprotectin assays.
In the first poster by Reinhard et al., 128 raw stool samples were collected from patients with signs and symptoms suggesting intestinal inflammation. These patients underwent endoscopic evaluation to determine if they had IBD or IBS. The samples were extracted using the BÜHLMANN CALEX® Cap stool extraction device and quantified on four different fecal calprotectin assays: BÜHLMANN fCAL® ELISA, fCAL® turbo (PETIA), Quantum Blue® fCAL extended lateral flow assay, and smartphone based IBDoc® fCAL home test. ROC curves were calculated for each method in respect of differentiating between IBS and IBD with area under the curve (AUC) values ranging from 0.827 (Samsung Galaxy S7 with IBDoc® to fCAL® turbo). The study concluded that all BÜHLMANN fecal calprotectin assays are very comparable and show an excellent clinical performance, irrespective of the method performed. Depending on the needs of the patients and their care team, either one of the methods or a combination of them can be used interchangeably.
In a second poster by Ohmann et al., characteristics of a recombinant calprotectin protein were presented. Native calprotectin exists as dimeric and tetrameric complex of MRP-8 and MRP-14 subunits. Using assays with different oligomeric states for standardization may result in inconsistent or conflicting outcomes. BÜHLMANN has developed a recombinant calprotectin (RCAL) that can be stably produced in large quantities. The recombinant protein has comparable immunological and biophysical behavior compared to the native protein and can be used as stable calibrator material for serum calprotectin assays.